Y-mAbs Therapeutics, Inc.
NASDAQ:YMAB
15.55 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q4 | 2018 Q3 | 2018 Q2 | 2018 Q1 | 2017 Q4 | 2017 Q3 | 2017 Q2 | 2017 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 18.461 | 22.798 | 19.931 | 23.363 | 20.454 | 20.751 | 20.251 | 31.447 | 12.537 | 10.797 | 10.486 | 9.598 | 8.965 | 10.951 | 5.383 | 20.75 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 3.014 | 2.147 | 2.039 | 2.645 | 4.649 | 2.083 | 2.02 | 2.475 | 1.24 | 1.831 | 1.461 | 0.55 | 0.41 | 0.093 | 2.203 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 18.461 | 19.784 | 17.784 | 21.324 | 17.809 | 16.102 | 18.168 | 29.427 | 10.062 | 9.557 | 8.655 | 8.137 | 8.415 | 10.541 | 5.29 | 18.547 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 1 | 0.868 | 0.892 | 0.913 | 0.871 | 0.776 | 0.897 | 0.936 | 0.803 | 0.885 | 0.825 | 0.848 | 0.939 | 0.963 | 0.983 | 0.894 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 11.168 | 12.341 | 13.267 | 13.388 | 15.358 | 12.055 | 13.418 | 19.787 | 22.453 | 26.42 | 22.912 | 28.757 | 23.131 | 19.778 | 21.579 | 24.011 | 21.005 | 30.059 | 18.622 | 16.827 | 19.66 | 14.494 | 12.511 | 11.041 | 8.731 | 8.293 | 6.204 | 6.625 | 3.076 | 2.303 | 2.303 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.63 | 11.636 | 10.393 | 8.125 | 6.931 | 4.699 | 4.14 | 3.742 | 3.037 | 2.684 | 1.965 | 1.275 | 2.65 | 0.766 | 0.761 | 0.761 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 13.613 | 17.232 | 11.425 | 11.135 | 10.2 | 11.27 | 12.251 | 10.793 | 13.626 | 23.082 | 13.438 | 15.138 | 13.988 | 13.475 | 11.97 | 14.63 | 11.636 | 10.393 | 8.125 | 6.931 | 4.699 | 4.14 | 3.742 | 3.037 | 2.684 | 1.965 | 1.275 | 2.65 | 0.766 | 0.761 | 0.761 |
| Other Expenses
| 0 | -0.17 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0.21 | 0 | 0 | 62.01 | 2.203 | 0 | 0 | 0 | 0 | 0 | 0 | 0.319 | 0 | -0.011 | 0 | 0 | 0.021 | 0.015 | 0 | 0 |
| Operating Expenses
| 24.781 | 29.573 | 24.692 | 24.523 | 25.558 | 23.325 | 25.669 | 30.58 | 36.079 | 49.502 | 36.35 | 43.895 | 37.119 | 33.253 | 33.549 | 38.641 | 32.641 | 40.452 | 26.747 | 23.758 | 24.359 | 18.634 | 16.253 | 14.078 | 11.415 | 10.258 | 7.479 | 9.275 | 3.842 | 3.041 | 3.041 |
| Operating Income
| -8.568 | -9.789 | -6.908 | -3.199 | -7.749 | -7.223 | -7.501 | -1.153 | -26.017 | -39.945 | -27.695 | -35.758 | -28.704 | -22.712 | -28.259 | -20.094 | -32.641 | -40.452 | -26.747 | -23.758 | -24.359 | -18.634 | -16.253 | -14.078 | -11.415 | -10.258 | -7.479 | -9.275 | -3.842 | -3.064 | -3.064 |
| Operating Income Ratio
| -0.464 | -0.429 | -0.347 | -0.137 | -0.379 | -0.348 | -0.37 | -0.037 | -2.075 | -3.7 | -2.641 | -3.726 | -3.202 | -2.074 | -5.25 | -0.968 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.916 | 0.64 | 0.439 | 2.406 | 0.189 | 1.1 | 1.111 | 2.31 | -1.509 | -1.186 | -0.373 | -1.135 | -0.154 | -0.225 | 62.01 | 0.161 | -0.191 | 0.059 | 0.568 | 0.622 | 0.437 | 0.598 | 0.319 | 0.018 | -0.011 | -0.047 | -0.004 | 0.021 | 0.015 | 0.023 | 0.023 |
| Income Before Tax
| -6.652 | -9.149 | -6.469 | -0.793 | -7.56 | -6.123 | -6.39 | 1.157 | -27.526 | -41.131 | -28.068 | -36.893 | -28.858 | -22.937 | 33.413 | -19.933 | -32.832 | -40.393 | -26.179 | -23.136 | -23.922 | -18.036 | -15.934 | -14.06 | -11.426 | -10.305 | -7.483 | -9.254 | -3.827 | -3.041 | -3.041 |
| Income Before Tax Ratio
| -0.36 | -0.401 | -0.325 | -0.034 | -0.37 | -0.295 | -0.316 | 0.037 | -2.196 | -3.809 | -2.677 | -3.844 | -3.219 | -2.095 | 6.207 | -0.961 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.346 | 0.1 | 0.16 | 0.195 | 0.187 | 0.179 | -1.293 | 1.558 | 1.509 | 1.186 | 0.373 | 1.135 | 0 | -0.216 | 0.338 | 2.086 | 0 | 0 | 0 | -0.079 | 0 | 0 | -0.019 | 0 | 0 | 0 | -7.479 | -9.275 | -3.842 | 0.023 | 0.023 |
| Net Income
| -6.998 | -9.249 | -6.629 | -0.988 | -7.747 | -6.302 | -5.097 | -0.401 | -29.035 | -42.317 | -28.441 | -36.893 | -28.858 | -22.937 | 33.413 | -19.933 | -32.832 | -40.393 | -26.179 | -23.136 | -23.922 | -18.036 | -15.934 | -14.06 | -11.426 | -10.305 | -7.483 | -9.254 | -3.827 | -3.041 | -3.041 |
| Net Income Ratio
| -0.379 | -0.406 | -0.333 | -0.042 | -0.379 | -0.304 | -0.252 | -0.013 | -2.316 | -3.919 | -2.712 | -3.844 | -3.219 | -2.095 | 6.207 | -0.961 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.16 | -0.21 | -0.15 | -0.023 | -0.18 | -0.14 | -0.12 | -0.009 | -0.66 | -0.97 | -0.65 | -0.85 | -0.66 | -0.53 | 0.8 | -0.48 | -0.82 | -1.01 | -0.66 | -0.61 | -0.7 | -0.53 | -0.47 | -0.41 | -0.42 | -0.32 | -0.22 | -0.28 | -0.11 | -0.17 | -0.17 |
| EPS Diluted
| -0.16 | -0.21 | -0.15 | -0.023 | -0.18 | -0.14 | -0.12 | -0.009 | -0.66 | -0.97 | -0.65 | -0.85 | -0.66 | -0.53 | 0.75 | -0.45 | -0.82 | -1.01 | -0.66 | -0.58 | -0.7 | -0.53 | -0.47 | -0.41 | -0.42 | -0.32 | -0.22 | -0.28 | -0.11 | -0.17 | -0.17 |
| EBITDA
| -8.568 | -9.636 | -6.749 | -3.038 | -7.749 | -7.223 | -7.501 | -1.153 | -25.791 | -39.757 | -27.5 | -35.758 | -28.559 | -22.712 | -28.129 | -17.891 | -32.548 | -40.352 | -26.661 | -23.758 | -24.311 | -18.614 | -16.253 | -14.064 | -11.406 | -10.252 | -7.479 | -9.275 | -3.842 | 0.023 | 0.023 |
| EBITDA Ratio
| -0.464 | -0.423 | -0.339 | -0.13 | -0.379 | -0.348 | -0.37 | -0.037 | -2.057 | -3.682 | -2.623 | -3.726 | -3.186 | -2.074 | -5.226 | -0.862 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |